<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Research Statement — Santosh Gothwal</title>

    <link rel="stylesheet" href="assets/css/tailwind.css">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat&display=swap" rel="stylesheet">

    <style>
        body {
            font-family: 'Montserrat', sans-serif;
        }
    </style>
</head>

<body class="flex flex-col min-h-screen bg-white">

    <!-- NAVBAR -->
    <div id="navbar"></div>
    <!-- LOAD NAVBAR + FOOTER -->
    <script src="common/include.js"></script>
    <script>
        loadHTML("navbar", "common/navbar.html").then(() => {

            const navToggle = document.getElementById('navToggle');
            const mobileMenu = document.getElementById('mobileMenu');
            const backdrop = document.getElementById('backdrop');

            function openMenu() {
                mobileMenu.classList.remove('scale-y-0', 'opacity-0');
                mobileMenu.classList.add('scale-y-100', 'opacity-100');
                backdrop.classList.remove('opacity-0', 'pointer-events-none');
            }

            function closeMenu() {
                mobileMenu.classList.add('scale-y-0', 'opacity-0');
                mobileMenu.classList.remove('scale-y-100', 'opacity-100');
                backdrop.classList.add('opacity-0', 'pointer-events-none');
            }

            navToggle?.addEventListener('click', () => {
                const isOpen = mobileMenu.classList.contains('scale-y-100');
                isOpen ? closeMenu() : openMenu();
            });

            backdrop?.addEventListener('click', closeMenu);
        });
    </script>

    <!-- MAIN CONTENT -->
    <main class="pt-28 pb-16 px-6">

        <div class="max-w-5xl mx-auto">

            <!-- Page Title -->
            <h1 class="text-3xl md:text-4xl font-bold text-gray-900 mb-6">
                Research Statement: Personalized Cancer Chemotherapy
            </h1>

            <!-- Hero Image -->
            <div class="rounded-3xl overflow-hidden shadow mb-10">
                <img src="images/statement/statement.png" class="w-full object-cover"
                    alt="Research statement illustration">
            </div>

            <!-- ================= CONTENT CARD ================= -->
            <div class="bg-[#EDEEE7] rounded-3xl p-8 md:p-12 shadow leading-relaxed text-gray-900">

                <!-- Lead Paragraph -->
                <p class="mb-8 text-lg md:text-xl
        first-letter:text-5xl first-letter:font-bold
        first-letter:pr-1 first-letter:float-left">
                    Effective cancer treatment depends on the chemotherapeutic responses in each patient.
                    Genetic alterations within tumor cells are not always common across individuals,
                    therefore responses to chemotherapies can vary widely.
                    Frontline therapies targeting DNA replication, DNA damage repair,
                    and Poly(ADP-ribose) polymerase (PARP) exploit defects in genome maintenance
                    to induce cancer cell death. However, recurrent driver mutations in tumors
                    frequently cause resistance to these chemotherapies and immunotherapies,
                    enabling tumors to evade therapeutic response and resulting in treatment failure.
                </p>

                <!-- Divider -->
                <div class="border-t border-gray-300 my-8"></div>

                <!-- Section 2 -->
                <p class="mb-6">
                    Several loss-of-function and gain-of-function mutations actively drive chemoresistance.
                    Notably, <strong>TP53 gain-of-function mutations</strong> promote genomic instability,
                    suppress apoptosis, alter chromatin regulation, and activate oncogenic transcriptional
                    programs. Additional driver mutations in
                    <strong>EGFR, BRAF, KRAS, PIK3CA, MYC, PTEN, BRCA1/2, ATM, and ATR</strong>
                    further shape therapeutic response by enhancing replication stress tolerance,
                    altering DNA repair pathway choice, or sustaining proliferative signaling.
                </p>

                <p class="mb-6">
                    Even in BRCA1/2-mutant tumors initially sensitive to PARP inhibitors,
                    secondary mutations can restore homologous recombination,
                    leading to acquired resistance and relapse.
                </p>

                <!-- Pull Quote -->
                <blockquote class="bg-white rounded-2xl border-l-4 border-gray-600
        p-6 my-10 italic text-lg text-gray-700 shadow-sm">
                    “Personalized chemotherapy begins with decoding mutation-driven vulnerabilities
                    within each tumor.”
                </blockquote>

                <!-- Section 3 -->
                <p class="mb-6">
                    In general chemotherapeutic practice, tumor-specific mutations are often not
                    characterized prior to the first treatment. This can activate compensatory
                    survival mechanisms through DNA repair pathways such as
                    <strong>non-homologous end joining (NHEJ)</strong> and
                    <strong>homologous recombination (HR)</strong>,
                    alongside R-loop accumulation, altered chromatin organization,
                    immune signaling reprogramming, and oncogene hyperactivation.
                </p>

                <!-- Diagram Hyperlink Placeholder -->
                <p class="mb-6">
                    These resistance-associated adaptations can facilitate secondary tumor evolution
                    and promote treatment failure.
                    (<a href="#diagram"
                        class="text-orange-700 font-semibold underline hover:text-orange-900 transition">
                        Hyperlink to Diagram
                    </a>)
                </p>

                <!-- Closing -->
                <p class="mt-8">
                    My long-term goal is to develop integrative systems that classify tumor-specific
                    mutations in cancer patients and predict optimal therapeutic strategies prior
                    to treatment initiation. By systematically integrating genomic analyses with
                    chemotherapeutic profiling of cancer biopsies in organoid, cell culture, and
                    xenograft models, my research aims to link specific mutations to drug responses,
                    support clinical decision-making, improve therapeutic efficacy, extend patient survival,
                    and ultimately advance the broader impact of personalized chemotherapy and precision oncology.
                </p>

            </div>
        </div>

    </main>

    <!-- FOOTER -->
    <div id="footer"></div>

    <script>
        loadHTML("footer", "common/footer.html");
    </script>

</body>

</html>